To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug ...

The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, with ...

The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar ...

The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including ...

In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first ...

The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...

The top legal stories in biosimilars from 2024 emphasize the ongoing struggle between ensuring timely patient access and ...

The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...

Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while ...

Number 3: Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and ...

Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, ...

The top 5 rheumatology biosimilar articles of 2024 focus on key developments in biosimilar approvals and treatment options. These include the FDA's approval of innovative formulations, such as a ...